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Increased arterial stiffness is an independent predictor of cardiovascular disease inde-
pendent from blood pressure. Recent studies have shed new light on the importance 
of inflammation on the pathogenesis of arterial stiffness. Arterial stiffness is associat-
ed with the increased activity of angiotensin II, which results in increased NADPH 
oxidase activity, reduced NO bioavailability and increased production of reactive ox-
ygen species. Angiotensin II signaling activates matrix metalloproteinases (MMPs) 
which degrade TGFβ precursors to produce active TGFβ, which then results in in-
creased arterial fibrosis. Angiotensin II signaling also activates cytokines, including 
monocyte chemoattractant protein-1, TNF-α, interleukin-1, interleukin-17 and inter-
leukin-6. There is also ample clinical evidence that demonstrates the association of 
inflammation with increased arterial stiffness. Recent studies have shown that reduc-
tions in inflammation can reduce arterial stiffness. In patients with rheumatoid arthri-
tis, increased aortic pulse wave velocity in patients was significantly reduced by anti 
tumor necrosis factor-α therapy. Among the major classes of anti hypertensive drugs, 
drugs that block the activation of the RAS system may be more effective in reducing 
the progression of arterial stiffness. Thus, there is rationale for targeting specific in-
flammatory pathways involved in arterial stiffness in the development of future 
drugs. Understanding the role of inflammation in the pathogenesis of arterial stiff-
ness is important to understanding the complex puzzle that is the pathophysiology of 
arterial stiffening and may be important for future development of novel treatments. 
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INTRODUCTION
Increase in arterial stiffness is a consequence of vascular fibrosis and elastic fiber 
degradation of the large arteries, with resulting in decreased in the arterial compli-
ance. Increased arterial stiffness is the major underlying cause for the increase in 
systolic blood pressure that is associated with aging. The increase in systolic blood 
pressure is an important reason for the adverse prognosis associated with increased 
arterial stiffness. However, arterial stiffness has been demonstrated to be a predic-
tor for increased risk for stroke, coronary artery disease and heart failure indepen-
dent from blood pressure.1-6 Although increased arterial stiffness is highly correlated 
with the aging process, it acts in concert with extrinsic factors such as hypertension, 
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tivity, reduced NO bioavailability and increased production 
of reactive oxygen species20-22 AngII signaling activates 
MMPs which degrade the TGFβ precursor to produce ac-
tive TGFβ. AngII signaling also activates cytokines includ-
ing monocyte chemoattractant protein-1 (MCP-1), TNF-α, 
Interleukin-1, Interleukin-17 and interleukin-6.20,23-26 Nec-
ropsy studies performed in aged human thoracic aorta dem-
onstrated increased levels of angiotensin converting en-
zyme, angiotensin II, angiotensin receptor type 1 MMPs 
and MCP-1, compared to young aorta, suggesting the like-
lihood for the significant role of inflammation in the patho-
genesis of arterial stiffening.20 The activation of the MCP-1/
CCR2 pathway, which has been demonstrated to play a sig-
nificant role in mediating arterial inflammation and remod-
eling, further stimulates arterial inflammation, increases ex-
pression of cell adhesion molecules, increases secretion of 
MMP, amplifies the activity of other cytokines and increas-
es vascular smooth muscle cell migration.19,27-29  Inflamma-
tory cytokines stimulate the local production of C-reactive 
protein (CRP) by vascular smooth muscle cells. CRP has 
an active role in promoting vascular inflammation and re-
ducing endothelial function.30-32 Recent studies have dem-
onstrated a significant association of high-sensitivity (hs)
CRP and arterial stiffness.33-35 Although hsCRP is a surro-
gate marker of vascular inflammation, CRP itself may play 
an active role in mediating arterial stiffness. For example, 
CRP may have a direct role in inducing endothelial dys-
function. As a consequence, endothelial dysfunction may 
result in increased  expression of proinflammatory cyto-
kines and cell adhesion molecules. The increased vascular 
inflammation will increase vascular fibrosis, smooth mus-
cle cell proliferation, and impair endothelial mediated vaso-
dilation, which will  subsequently lead to increase in arteri-
al stiffness.32,36,37 Oxidative stress appears to play a role in 
the pathogenesis of arterial stiffness, as oxidative injury may 
result in increased vascular inflammation and increased cel-
lular proliferation, which may subsequently lead to impaired 
arterial elasticity.38
CLINICAL EVIDENCE OF THE 
ASSOCIATION OF INFLAMMATION 
AND ARTERIAL STIFFNESS
  
hsCRP is an inflammatory biomarker that is widely used to 
determine the degree of low grade systemic inflammation. 
Numerous studies have demonstrated that hsCRP is an inde-
high sodium intake, diabetes, dyslipidemia, obesity, neuro-
hormonal system activation interact with structural elements 
of the vasculature to accelerate this aging process.5-10 These 
factors result in endothelial dysfunction, vascular inflamma-
tion, vascular smooth muscle cell hyperplasia, increased col-
lagen, and elastin degradation.7,11,12 Recent studies have shed 
new light on the importance of inflammation in the patho-
genesis of arterial stiffness. This review will discuss the role 
of inflammation in the pathogenesis of arterial stiffness.
 MECHANISMS OF ARTERIAL 
STIFFNESS: CHANGES IN THE 
STRUCTURAL, CELLULAR 
COMPONENTS
  
Arterial stiffness is characterized by thickening of the inti-
ma-media, accompanied by an increase in the central arterial 
lumen,13 endothelial dysfunction, vascular smooth muscle 
cell hyperplasia, increased collagen, and elastin degradation. 
The increased fragmentation of elastin molecules that is 
characteristic of arterial stiffness is mediated by activation 
of various types of matrix metalloproteinases (MMP) and 
serine proteinases.7,14 The activity of MMP is increased in 
intima media of aged aortic tissues and is accompanied by 
decreased activity of TIMP-2, an endogenous inhibitor of 
MMP. The relative imbalance between MMP/TIMP-2 ac-
tivity is important in ECM remodeling and subsequent arte-
rial stiffening.15,16 In addition to elastin degradation, the col-
lagenolytic activity of MMP results in creation of uncoiled, 
stiffer collagen.7 Also, degradation of basement membrane 
ECM by activated MMPs and stimulation of chemotaxis 
may result in increased smooth muscle migration and pro-
liferation in the intima.16,17
The increased MMP activity may be mediated by in-
creased activity of the renin angiotensin system, oxidative 
stress, endothelial dysfunction, AGE stimulated activation of 
RAGE, and increased activity of proinflammatory cytokines 
or cell adhesion molecules.18-20 
 THE ROLE OF INFLAMMATION IN 
ARTERIAL STIFFNESS: THE BASIC 
MECHANISM
  
Arterial stiffness is associated with increased activity of an-
giotensin II, which results in increased NADPH oxidase ac-
Sungha Park and Edward G. Lakatta 
Yonsei Med J   http://www.eymj.org   Volume 53   Number 2   March 2012260
cific inflammatory pathways involved in arterial stiffness in 
the development of future drugs. 
CONCLUSION
The importance of inflammation in the pathogenesis of ar-
terial stiffness has been amply demonstrated. Understand-
ing the role of inflammation in the pathogenesis of arterial 
stiffness is important in understanding the complex puzzle 
that is the pathophysiology of arterial stiffening and is im-
portant for future development of novel treatments. 
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